Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LXT-101

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND The thermo-sensitive in situ gels based on copolymers are attractive as an injectable drug delivery carriers for… Expand
2013
2013
LXT-101, a cationic peptide is a novel antagonist of gonadotropin-releasing hormone (GnRH) for prostate cancer treatment. However… Expand
  • figure 2
  • figure 4
  • figure 6
2011
2011
Objectives  Multivesicular liposomes (MVLs) are often used as an appropriate carrier for delivering peptides due to high drug… Expand
2011
2011
The introduction of luteinizing hormone-releasing hormone (LHRH) analogs and their antagonists is revolutionizing the treatment… Expand
2009
2009
Using a simple method to determine the interaction between peptide and lipid bilayer and then deciding how to modify formulation… Expand
2008
2008
This paper developed a sensitive and specific liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/MS) method… Expand
2006
2006
A sustained release poly(DL-lactide-co-glycolide) (PLGA) microsphere delivery system to treat prostate cancer for a luteinizing… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2006
2006
LXT-101 is a newly developed GnRH (gonadotropin-releasing hormone) analogue. In this study, the in vivo pharmacological profile… Expand
2005
2005
AIM The biological characterization of LXT-101 was investigated in vivo using intact male rats and nude mice bearing xenografts… Expand
2004
2004
AIM: To investigate the pharmacological effect of LXT-101 on serum testosterone level in intact male rats. METHODS: Ratswere… Expand